The company manufactures and trades a wide range of products including polyester staple fibre (PSF), soda ash, general and specialty chemicals, pharmaceuticals, nutraceuticals, animal health products and agricultural products. In May 2024, Lucky acquired Pfizer Pakistan's sole manufacturing facility in Pakistan, strengthening its pharmaceutical and healthcare segments. The company benefits from established operations and diversified revenue streams across industrial and consumer sectors.
Cyborg Score Rationale
As of February 2026, the company has a market cap of $447M with trailing 12-month revenue of $418M. Net profit mounted by 23.38% to Rs.6218.333 million in H1FY25 with EPS of Rs.67.33. The company maintains a VIS credit rating of AA for Medium to Long Term and A1+ for Short Term with positive outlook.
Top Insights
Company was renamed to Lucky Core Industries in 2022, signifying rebranding and renewed strategic direction under Yunus Brothers Group ownership
Company exports products and services to Bangladesh, China, Sri Lanka, United States, UAE and other countries, reducing domestic market concentration risk
Lucky Cement Limited holds 55% shares of LCI, providing strong parent company backing and synergistic opportunities
Company undertook major acquisitions of Cirin Pharmaceuticals, Wyeth Pakistan, and Pfizer Pakistan, demonstrating aggressive inorganic growth strategy
Named Competitors
Chemical Manufacturing — Pakistan-based chemical manufacturer
Recent Developments
(May 2024) Acquired Pfizer Pakistan's manufacturing facility in Karachi, expanding pharmaceutical production capacity
(H1 FY25) Net profit growth of 23.38% with improved net profit margin from 8.37% to 10%
(December 2022) Company rebranded from ICI Pakistan Limited to Lucky Core Industries Limited
Open the full interactive Lucky Core Industries Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.